Vaccine problems, plans scrutinized during Senate hearing

Facing criticism for wasting hundreds of millions of dollars on anthrax vaccines, a top Health and Human Services official said Tuesday that the agency needs more money to prevent similar problems.

A Government Accountability Office report released Tuesday detailed HHS missteps, including losing tens of millions of dollars on expiring vaccines and awarding a $877 million contract that the agency canceled after an unproven pharmaceutical company called VaxGen failed to meet what HHS acknowledges were unrealistic expectations for a new vaccine.

The report drew rebukes at a Senate Homeland Security and Governmental Affairs hearing on bioterrorism preparation, held to coincide with the sixth anniversary of anthrax attacks that killed six people in 2001.

"The Department of Health and Human Services' efforts to develop a second generation anthrax vaccine -- to improve upon the 30-year-old-technology we have in the stockpile -- has, in a word, failed," Senate Homeland Security and Governmental Affairs Chairman Joseph Lieberman, I-Conn., said in an opening statement. "This is a disappointing failure that has put us back at square one after years of work."

Gerald Parker, principal deputy assistant secretary in HHS' office of the assistant secretary for preparedness and response, observed that anthrax vaccines are only one piece of efforts by HHS and the Homeland Security Department to prepare for biological threats through their $5.6 billion BioShield project.

Recognizing that it had been contracting too early in the risky drug development process, the agency is working to buy vaccines that are "further down the pipeline," Parker said.

For commercial markets, drug makers often raise capital to pay for development costs. But with no private market for biodefense products, big pharmaceutical companies have not competed for contracts to sell vaccines to the government, causing agencies to rely on smaller, less risk-averse companies.

According to GAO, established drug-makers have also stayed away because a lack of clear requirements from government departments places additional risks on contractors. Lieberman agreed with those sentiments. "We have to find a way to entice the big pharmaceutical companies to get into this," he said.

Parker said $189 million in the president's fiscal 2008 budget request for advanced drug development will spur needed research. The Biodefense and Pandemic Vaccine and Drug Development Act of 2006 calls for advanced biodefense research, but Congress thus far has not funded the so-called BARDA Act.

Tara O'Toole, director of the Center for Biosecurity at the University of Pittsburgh Medical Center, said the gap between the government's goals for guarding against biological terrorism and its spending is much larger than most involved realize. "Five billion [dollars] is much less than we're going to need," O'Toole said.

Stay up-to-date with federal news alerts and analysis — Sign up for GovExec's email newsletters.
FROM OUR SPONSORS
JOIN THE DISCUSSION
Close [ x ] More from GovExec
 
 

Thank you for subscribing to newsletters from GovExec.com.
We think these reports might interest you:

  • Sponsored by G Suite

    Cross-Agency Teamwork, Anytime and Anywhere

    Dan McCrae, director of IT service delivery division, National Oceanic and Atmospheric Administration (NOAA)

    Download
  • Data-Centric Security vs. Database-Level Security

    Database-level encryption had its origins in the 1990s and early 2000s in response to very basic risks which largely revolved around the theft of servers, backup tapes and other physical-layer assets. As noted in Verizon’s 2014, Data Breach Investigations Report (DBIR)1, threats today are far more advanced and dangerous.

    Download
  • Federal IT Applications: Assessing Government's Core Drivers

    In order to better understand the current state of external and internal-facing agency workplace applications, Government Business Council (GBC) and Riverbed undertook an in-depth research study of federal employees. Overall, survey findings indicate that federal IT applications still face a gamut of challenges with regard to quality, reliability, and performance management.

    Download
  • PIV- I And Multifactor Authentication: The Best Defense for Federal Government Contractors

    This white paper explores NIST SP 800-171 and why compliance is critical to federal government contractors, especially those that work with the Department of Defense, as well as how leveraging PIV-I credentialing with multifactor authentication can be used as a defense against cyberattacks

    Download
  • Toward A More Innovative Government

    This research study aims to understand how state and local leaders regard their agency’s innovation efforts and what they are doing to overcome the challenges they face in successfully implementing these efforts.

    Download
  • From Volume to Value: UK’s NHS Digital Provides U.S. Healthcare Agencies A Roadmap For Value-Based Payment Models

    The U.S. healthcare industry is rapidly moving away from traditional fee-for-service models and towards value-based purchasing that reimburses physicians for quality of care in place of frequency of care.

    Download
  • GBC Flash Poll: Is Your Agency Safe?

    Federal leaders weigh in on the state of information security

    Download

When you download a report, your information may be shared with the underwriters of that document.